Universe Pharmaceuticals (UPC) Receivables - Other (2021 - 2025)

Universe Pharmaceuticals has disclosed Receivables - Other across 5 years of filings, most recently posting $2.3 billion for Q3 2025.

• Receivables - Other for Q3 2025 came in at $2.3 billion, down 59.75% year-over-year; the trailing twelve-month figure through Sep 2025 was $2.3 billion (down 59.75% YoY), and the FY2025 annual result was $2.3 billion, down 59.75% from the prior year.
• Receivables - Other came in at $2.3 billion for Q3 2025 at Universe Pharmaceuticals, down from $5.7 billion in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $5.7 billion in Q3 2024 to a low of $236982.0 in Q3 2021.
• The 5-year median for Receivables - Other is $1.9 million (2023), against an average of $1.6 billion.
• Across the five-year window, Receivables - Other soared 294996.63% in 2024 and plunged 59.75% in 2025, its largest moves.
• Universe Pharmaceuticals' Receivables - Other stood at $236982.0 in 2021, then jumped by 50.34% to $356290.0 in 2022, then surged by 438.96% to $1.9 million in 2023, then jumped by 294996.63% to $5.7 billion in 2024, then slumped by 59.75% to $2.3 billion in 2025.
• The last three Receivables - Other figures came in at $2.3 billion (Q3 2025), $5.7 billion (Q3 2024), and $1.9 million (Q3 2023), per Business Quant data.